Early Identification and Treatment of Rare Heart Muscle Diseases
Tests imaging-guided risk assessment to prevent heart failure in people with rare cardiomyopathies.
Plain-language title generated from the registry record
Registry title: Early Identification and Treatment of Rare Cardiomyopathy Cohorts
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06794710, who can take part
Where in China
- RenJi HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT06794710
- Record updated
- 27 January 2025
- Original description
This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.Read full original descriptionShow less
Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)
This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.
Inclusion: Age 18-75 years old; Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments; No history of structural heart disease, and the Framingham score \<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography/coronary CT/exercise platelet); Creatinine clearance ≥50ml/min (Cockcroft-Gault formula); LVEF ≥50% assessed by Echocardiography; QT interval \< 470 ms; Providing written informed consent.
Exclusion: History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure; Presence of acute/chronic renal impairment (GFR \<50/ml/min/1.73m2); Presence of contraindications to CMR.